These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 37187749)

  • 1. Efficacy and safety of rituximab for primary membranous nephropathy with different clinical presentations: a retrospective study.
    Zhang S; Huang J; Dong J; Li Z; Sun M; Sun Y; Chen B
    Front Immunol; 2023; 14():1156470. PubMed ID: 37187749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A novel approach to rapid induction of remission in primary membranous nephropathy].
    Dobronravov VA; Bystrova OB; Kochoyan ZS; Fomicheva EN
    Ter Arkh; 2021 Jun; 93(6):706-712. PubMed ID: 36286838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparison of efficacy and safety of immunosuppressive therapy and rituximab targeting therapy in idiopathic membranous nephropathy].
    Zhao R; Fan R; Pan Y; Guo Y; Han Y; Wang Y; Zhang J; Yang H; Yu D; Chen W
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2024 Jul; 40(7):636-641. PubMed ID: 39179407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach.
    Wang S; Deng Z; Wang Y; Bao W; Zhou S; Cui Z; Zheng D
    BMC Nephrol; 2023 May; 24(1):146. PubMed ID: 37237260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter retrospective study on comparing the efficacy and safety of the therapy of intermittent cyclophosphamide and corticosteroids versus rituximab for primary membranous nephropathy.
    Wang Y; Ma X; Yang X; Bai S; Zang X; Liao L; Wang Y; Lv Z; Zhang T; Zhuang S; Liu N
    Ren Fail; 2024 Dec; 46(2):2409353. PubMed ID: 39351796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose rituximab is poorly effective in patients with primary membranous nephropathy.
    Moroni G; Depetri F; Del Vecchio L; Gallelli B; Raffiotta F; Giglio E; Brunini F; D'Amico M; Longhi S; Radice A; Messa P; Sinico RA
    Nephrol Dial Transplant; 2017 Oct; 32(10):1691-1696. PubMed ID: 27387472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of rituximab and short-term glucocorticoids in the treatment of anti-phospholipase A
    Ma Q; Li M; Xu G
    Clin Exp Med; 2023 Dec; 23(8):5337-5343. PubMed ID: 37688683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of Rituximab, Low-Dose Cyclophosphamide, and Prednisone for Primary Membranous Nephropathy: A Case Series With Extended Follow Up.
    Zonozi R; Laliberte K; Huizenga NR; Rosenthal JK; Jeyabalan A; Collins AB; Cortazar FB; Niles JL
    Am J Kidney Dis; 2021 Dec; 78(6):793-803. PubMed ID: 34174365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimized rituximab regimen versus recommended regimen for idiopathic membranous nephropathy: A single-center retrospective cohort study.
    Yan P; Fang X; Ke B
    Int Immunopharmacol; 2024 Mar; 130():111718. PubMed ID: 38377859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy.
    van den Brand JAJG; Ruggenenti P; Chianca A; Hofstra JM; Perna A; Ruggiero B; Wetzels JFM; Remuzzi G
    J Am Soc Nephrol; 2017 Sep; 28(9):2729-2737. PubMed ID: 28487395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of rituximab in patients with PLA2R-associated membranous nephropathy and malignancy.
    Guo Y; Ren M; Wang Y; Zhai Z; Yu L; Wang L; Tang L
    Int Immunopharmacol; 2024 Jan; 126():111327. PubMed ID: 38056198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of rituximab in the treatment of membranous nephropathy: A systematic review and meta-analysis.
    Lu W; Gong S; Li J; Luo H; Wang Y
    Medicine (Baltimore); 2020 Apr; 99(16):e19804. PubMed ID: 32311997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of Rituximab and Low-dose Tacrolimus in the Treatment of Refractory Membranous Nephropathy: A Retrospective Cohort Study.
    Chen X; Jiao S; Li S; Li J; Li P; Song F; Yan Z
    Balkan Med J; 2023 Jul; 40(4):287-293. PubMed ID: 37260416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy.
    Ruggenenti P; Debiec H; Ruggiero B; Chianca A; Pellé T; Gaspari F; Suardi F; Gagliardini E; Orisio S; Benigni A; Ronco P; Remuzzi G
    J Am Soc Nephrol; 2015 Oct; 26(10):2545-58. PubMed ID: 25804280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of the domain specific PLA2R antibodies for clinical remission in patients with primary membranous nephropathy: A retrospective study.
    Zhou K; Zhou J; Zhou L; Xue J; Liu B; Zhang Z; Zhang X; Cai T; Shao S; Huang B; Zhang Y; Hu Z; Wang L; Liu X
    PLoS One; 2024; 19(5):e0302100. PubMed ID: 38718066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of low or standard rituximab-based protocols and comparison to Ponticelli's regimen in membranous nephropathy.
    Fenoglio R; Baldovino S; Sciascia S; De Simone E; Del Vecchio G; Ferro M; Quattrocchio G; Naretto C; Roccatello D
    J Nephrol; 2021 Apr; 34(2):565-571. PubMed ID: 32594370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Long-term efficacy of low-dose rituximab treatment in patients with primary membranous nephropathy].
    Qi Y; Jia JY; Gu QH; Zheng ZF; Li LN; Li D; Jia ZH; Xue Y; Yan TK
    Zhonghua Yi Xue Za Zhi; 2022 Nov; 102(40):3201-3206. PubMed ID: 36319174
    [No Abstract]   [Full Text] [Related]  

  • 18. PLA2R-IgG4 antibody as a predictive biomarker of treatment effectiveness and prognostic evaluation in patients with idiopathic membranous nephropathy: a retrospective study.
    Huang Y; Zhou J; Zhou K; Huang B; Xue J; Zhang X; Liu B; Zhang Z; Zhou L; Cai T; Zhang Y; Hu Z; Wang L; Liu X
    PeerJ; 2022; 10():e14193. PubMed ID: 36248712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of rituximab in patients with idiopathic membranous nephropathy: a case series and literature review.
    Jeon SJ; Kim JH; Noh HW; Lee GY; Lim JH; Jung HY; Cho JH; Choi JY; Kim CD; Kim YL; Park SH
    Korean J Intern Med; 2022 Jul; 37(4):830-840. PubMed ID: 35421909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome.
    von Groote TC; Williams G; Au EH; Chen Y; Mathew AT; Hodson EM; Tunnicliffe DJ
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD004293. PubMed ID: 34778952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.